Get the Stockscreener App
1.11
0.89%
-0.01
After Hours:
1.13
0.02
+1.80%
Femasys Inc stock is traded at $1.11, with a volume of 71,074.
It is down -0.89% in the last 24 hours and down -5.13% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
See More
Previous Close:
$1.12
Open:
$1.11
24h Volume:
71,074
Relative Volume:
0.52
Market Cap:
$24.52M
Revenue:
$1.07M
Net Income/Loss:
$-14.25M
P/E Ratio:
-1.1563
EPS:
-0.96
Net Cash Flow:
$-11.42M
1W Performance:
-0.89%
1M Performance:
-5.13%
6M Performance:
-28.39%
1Y Performance:
-62.75%
1-Day Range:
$1.09
$1.13
1-Week Range:
$1.09
$1.1599
52-Week Range:
$0.734
$4.75
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Femasys Inc Stock (FEMY) Latest News
Femasys announes infertility clinic customers from coast to coast - TipRanks
Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewswire
Femasys Announces Infertility Clinic Customers from Coast to Coast - StockTitan
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com India
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Femasys secures distribution partnerships for commercialization of FemaSeed - TipRanks
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - StockTitan
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Yahoo Finance
Items Tagged with 'Femchec' - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com India
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com
Femasys Femchec receives FDA clearance - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec By Investing.com - Investing.com UK
Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check - StockTitan
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - GlobeNewswire
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - Yahoo Finance
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - MSN
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - Yahoo Finance
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Femasys Inc (FEMY)’s stock price range in the last year - US Post News
Stocks of Femasys Inc (FEMY) are poised to climb above their peers - SETE News
Femasys Releases Updated Corporate Presentation Online - TipRanks
Femasys Inc (FEMY) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Femasys secures CE mark certification for FemVue MINI solution - Yahoo Finance
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys gains European and Canadian approval for FemVue MINI - Investing.com
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution - GlobeNewswire
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution - Yahoo Finance
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters - GlobeNewswire
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters - StockTitan
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event - StockTitan
Femasys (NASDAQ:FEMY) Stock Quotes, Forecast and News Summary - Benzinga
Chardan Capital Lowers Femasys (NASDAQ:FEMY) Price Target to $10.00 - Defense World
Femasys (NASDAQ:FEMY) PT Lowered to $12.00 at HC Wainwright - Defense World
Femasys Second Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
FEMY’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Femasys stock target cut to $12 amid sales headwinds By Investing.com - Investing.com Canada
Femasys stock target cut to $12 amid sales headwinds - Investing.com India
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update - GlobeNewswire
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update - Yahoo Finance
Richard Spector Named Chief Commercial Officer At Femasys - MPO-mag
Femasys Inc (FEMY) stock analysis: A comprehensive overview - US Post News
Femasys Inc. (NASDAQ:FEMY) Sees Significant Increase in Short Interest - American Banking and Market News
Femasys Inc. (NASDAQ:FEMY) Short Interest Update - Defense World
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):